Sofie Graner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Sofie Graner has a total of 50 co-authors. Here are the top co-authors by number of shared publications:
- Verena Sengpiel
Department of Obstetrics and Gynecology Sahlgrenska University Hospital Gothenburg Sweden
3 shared publications - Ylva Carlsson
Department of Obstetrics and Gynecology, Region Västra Götaland, Sahlgrenska University Hospital, Gothenburg, Sweden
3 shared publications - Anna Wessberg
Institute of Health and Care Sciences Sahlgrenska Academy, University of Gothenburg Gothenburg Sweden
2 shared publications - Helena Kopp Kallner
Department of Clinical Sciences at Danderyd Hospital, Karolinska Institutet
2 shared publications - Ingrid Mogren
Department of Clinical Sciences, Obstetrics and Gynecology, Umeå University, Umeå, Sweden
2 shared publications - Joseph Ntaganira
Department of Epidemiology and Biostatistics, School of Public health, College of Medicine and Health Sciences, University of Rwanda, Kigali, Rwanda
2 shared publications
Latest Publications
- Open Access
The OPTION trial: outpatient induction of labour – study protocol for a prospective, non-inferiority, multicentre randomised controlled trial
Introduction: Sweden, as many other high-income countries, has adopted guidelines to offer induction of labour at 41+0 gestational weeks to decrease the risk for perinatal death. As more than 20% of the pregnant population reach this gestational age, and along with other contributing factors, induction rates have increased up to 30% in many countries. Both women and care providers have raised the question if outpatient induction could be a convenient, safe and economic alternative, reducing the burden on inpatient care in maternity hospitals. Before introducing outpatient induction into clinical routine, studies need to assure safety for the child and woman as well as efficacy of the method. Method and analysis: A register-based randomised controlled multicentre non-inferiority trial to study if outpatient induction in low-risk inductions is (1) as safe for the child (perinatal composite of mortality and morbidity) and (2) as effective (proportion of vaginal deliveries) as inpatient induction at the hospital. Secondary outcomes are further health outcomes, experiences of pregnant women, partners and care providers, health economics and future pregnancy outcome. Participating women with a singleton pregnancy and unripe cervix between 37+0 and 41+6 gestational weeks planned for low-risk induction will undergo induction of labour with either a balloon catheter or oral misoprostol according to clinical practice at the study site and the woman’s informed choice. Randomisation will allocate women to either outpatient (home or patient hotel) or inpatient induction (standard care). Women undergoing outpatient induction can remain at home for up to 2 days, with an assessment after 24 hours including cardiotocography. Once active labour ensues, all women will receive standard care in the hospital. The assessment of non-inferiority will involve a two-sided 95% CI and 80% power, requiring randomisation of 8891 women to ensure a probability of at least 0.80 that the upper limit of a two-sided 95.7% CI for a difference in the primary safety outcome is below the non-inferiority margin of 1.5%. 31 of the 45 delivery units in Sweden are currently recruiting. Data will be collected from the electronic case report form and Swedish healthcare registers. Questionnaire and qualitative interview-based studies will be performed to explore experiences of pregnant women, partners and care providers. Additionally, a health economic evaluation will be performed. Ethics and dissemination: The Swedish Ethical Review Authority approved the study (3 June 2020; 2020-02675 with amendments 2021-03045, 2022-00865-02, 2023-01252-02, 2024-00560-02, 2024-2024-04597-02). The Swedish Medical Products Agency approved the study for the medication arm (25 August 2020, EudraCT number: 2020-000233-41; 5.1-2020-60240 with amendments 5.1-2022-73500, 5.1-2023-630). Due to changed regulation, in 2023, the study medication arm was transferred and approved by the European Medicines Agency (23 October 2023, EU CT Number: 2023-507164-39-00; CTIS 5.1.2-2023-099775 with amendments 5.1.2-2024-081916, 5.1.2-2025-036291). The Swedish Medical Products Agency approved the study for the medical device arm (6 April 2021, CIV-ID: CIV-20-09-034712; 5.1-2021-14812 with amendments 5.1-2022-14252, 5.1-2023-596, 5.1-2024-8886, 5.1-2024-55554). The medical device arm was transferred to Regulation (EU) 2017/745 (23 December 2024, 5.1-2025-24242 and amendment 5.1-2025-6050). The study will involve more than 80% of all delivery units in Sweden, which will allow for a smooth implementation of any new routine after the study’s conclusion. Results will be published in relevant scientific journals, presented at national and international conferences, and communicated to participants and relevant institutions through the Outpatient Induction study homepage ( www.optionstudien.se ), the webinars of the Swedish Network for National Clinical Studies in Obstetrics and Gynecology ( www.snaks.se ) as well as social and public media. Trial registration number: EudraCT No: 2020-000233-41, after transfer to the European Medicines Agency EU CT Number: 2023-507164-39-00; CIV-ID 20-09-034712.
Open AccessThe OPTION trial: outpatient induction of labour – study protocol for a prospective, non-inferiority, multicentre randomised controlled trial
Introduction: Sweden, as many other high-income countries, has adopted guidelines to offer induction of labour at 41+0 gestational weeks to decrease the risk for perinatal death. As more than 20% of the pregnant population reach this gestational age, and along with other contributing factors, induction rates have increased up to 30% in many countries. Both women and care providers have raised the question if outpatient induction could be a convenient, safe and economic alternative, reducing the burden on inpatient care in maternity hospitals. Before introducing outpatient induction into clinical routine, studies need to assure safety for the child and woman as well as efficacy of the method. Method and analysis: A register-based randomised controlled multicentre non-inferiority trial to study if outpatient induction in low-risk inductions is (1) as safe for the child (perinatal composite of mortality and morbidity) and (2) as effective (proportion of vaginal deliveries) as inpatient induction at the hospital. Secondary outcomes are further health outcomes, experiences of pregnant women, partners and care providers, health economics and future pregnancy outcome. Participating women with a singleton pregnancy and unripe cervix between 37+0 and 41+6 gestational weeks planned for low-risk induction will undergo induction of labour with either a balloon catheter or oral misoprostol according to clinical practice at the study site and the woman’s informed choice. Randomisation will allocate women to either outpatient (home or patient hotel) or inpatient induction (standard care). Women undergoing outpatient induction can remain at home for up to 2 days, with an assessment after 24 hours including cardiotocography. Once active labour ensues, all women will receive standard care in the hospital. The assessment of non-inferiority will involve a two-sided 95% CI and 80% power, requiring randomisation of 8891 women to ensure a probability of at least 0.80 that the upper limit of a two-sided 95.7% CI for a difference in the primary safety outcome is below the non-inferiority margin of 1.5%. 31 of the 45 delivery units in Sweden are currently recruiting. Data will be collected from the electronic case report form and Swedish healthcare registers. Questionnaire and qualitative interview-based studies will be performed to explore experiences of pregnant women, partners and care providers. Additionally, a health economic evaluation will be performed. Ethics and dissemination: The Swedish Ethical Review Authority approved the study (3 June 2020; 2020-02675 with amendments 2021-03045, 2022-00865-02, 2023-01252-02, 2024-00560-02, 2024-2024-04597-02). The Swedish Medical Products Agency approved the study for the medication arm (25 August 2020, EudraCT number: 2020-000233-41; 5.1-2020-60240 with amendments 5.1-2022-73500, 5.1-2023-630). Due to changed regulation, in 2023, the study medication arm was transferred and approved by the European Medicines Agency (23 October 2023, EU CT Number: 2023-507164-39-00; CTIS 5.1.2-2023-099775 with amendments 5.1.2-2024-081916, 5.1.2-2025-036291). The Swedish Medical Products Agency approved the study for the medical device arm (6 April 2021, CIV-ID: CIV-20-09-034712; 5.1-2021-14812 with amendments 5.1-2022-14252, 5.1-2023-596, 5.1-2024-8886, 5.1-2024-55554). The medical device arm was transferred to Regulation (EU) 2017/745 (23 December 2024, 5.1-2025-24242 and amendment 5.1-2025-6050). The study will involve more than 80% of all delivery units in Sweden, which will allow for a smooth implementation of any new routine after the study’s conclusion. Results will be published in relevant scientific journals, presented at national and international conferences, and communicated to participants and relevant institutions through the Outpatient Induction study homepage ( www.optionstudien.se ), the webinars of the Swedish Network for National Clinical Studies in Obstetrics and Gynecology ( www.snaks.se ) as well as social and public media. Trial registration number: EudraCT No: 2020-000233-41, after transfer to the European Medicines Agency EU CT Number: 2023-507164-39-00; CIV-ID 20-09-034712.
- Open Access
- 18 April 2025
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 104 (7) , 1399-1409
Moral distress among maternity and neonatal healthcare workers during the COVID‐19 pandemic in Sweden: Results from the COPE staff longitudinal cohort study
Introduction: Moral distress arises when healthcare workers face difficult decisions without adequate information and/or when patient care is compromised due to limited resources, communication issues, or altered work routines in exceptional circumstances. While moral distress in maternity and neonatal healthcare workers (MNHCWs) has been noted, its prevalence, intensity, and impact on well‐being and turnover in Sweden remain unexplored. The aim of this study was to investigate the level of disturbance and frequency of experiencing moral distress among Swedish MNHCWs during the COVID‐19 pandemic and the effects on MNHCWs' well‐being and intention to leave their job.Material and Methods: A longitudinal cohort study was conducted during January–May 2021 (n = 645) and January–March 2022 (n = 503), utilizing the Moral Distress Scale‐Revised (MDS‐R). The study was set in hospital‐based maternity and neonatal units across all 21 Swedish healthcare regions and included midwives, physicians, registered nurses, and assistant nurses. Quantitative and descriptive analyses were performed, with comparisons of moral distress levels between time points and professions. The main outcome measures were moral distress (level of disturbance and frequency) and intention to leave their job.Results: Among the respondents, 6%–47% reported being frequently exposed to morally challenging situations, and 51%–91% reported a high level of disturbance in connection to such situations. Uncertain staffing, continuity‐of‐care challenges, and limited opportunities for patient/family counseling posed frequent moral challenges across time and professions. Of the respondents, 14% in 2021 and 18% in 2022 considered leaving their jobs due to moral distress. There were no overall significant differences in outcomes between the two time points.Conclusions: Swedish MNHCWs commonly experienced moral distress during the COVID‐19 pandemic. Interventions targeting underlying reasons may be needed to ensure the well‐being of MNHCWs in situations when the healthcare system is under strained working conditions.
- 18 April 2025
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 104 (7) , 1399-1409
Open AccessMoral distress among maternity and neonatal healthcare workers during the COVID‐19 pandemic in Sweden: Results from the COPE staff longitudinal cohort study
Introduction: Moral distress arises when healthcare workers face difficult decisions without adequate information and/or when patient care is compromised due to limited resources, communication issues, or altered work routines in exceptional circumstances. While moral distress in maternity and neonatal healthcare workers (MNHCWs) has been noted, its prevalence, intensity, and impact on well‐being and turnover in Sweden remain unexplored. The aim of this study was to investigate the level of disturbance and frequency of experiencing moral distress among Swedish MNHCWs during the COVID‐19 pandemic and the effects on MNHCWs' well‐being and intention to leave their job.Material and Methods: A longitudinal cohort study was conducted during January–May 2021 (n = 645) and January–March 2022 (n = 503), utilizing the Moral Distress Scale‐Revised (MDS‐R). The study was set in hospital‐based maternity and neonatal units across all 21 Swedish healthcare regions and included midwives, physicians, registered nurses, and assistant nurses. Quantitative and descriptive analyses were performed, with comparisons of moral distress levels between time points and professions. The main outcome measures were moral distress (level of disturbance and frequency) and intention to leave their job.Results: Among the respondents, 6%–47% reported being frequently exposed to morally challenging situations, and 51%–91% reported a high level of disturbance in connection to such situations. Uncertain staffing, continuity‐of‐care challenges, and limited opportunities for patient/family counseling posed frequent moral challenges across time and professions. Of the respondents, 14% in 2021 and 18% in 2022 considered leaving their jobs due to moral distress. There were no overall significant differences in outcomes between the two time points.Conclusions: Swedish MNHCWs commonly experienced moral distress during the COVID‐19 pandemic. Interventions targeting underlying reasons may be needed to ensure the well‐being of MNHCWs in situations when the healthcare system is under strained working conditions.
- Open Access
- 30 March 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 162 (3) , 989-997
The COPE Staff study: Study description and initial report regarding job satisfaction, work‐life conflicts, stress, and burnout among Swedish maternal and neonatal healthcare workers during the COVID‐19 pandemic
Objective: To describe the study design of the COPE Staff cohort study on working conditions for maternal and neonatal healthcare workers (MNHCWs), and present baseline data regarding job satisfaction, work‐life conflicts, stress, and burnout.Methods: Between January and April 2021, 957 MNHCWs (administrative and medical staff) completed a baseline survey. Average levels of job satisfaction, work‐life conflicts, stress, and burnout, and associations to perceived workload were assessed.Results: The average levels of job satisfaction, work‐life conflicts, stress, and burnout were 68.6 (95% confidence interval [CI] 64.3–72.8), 42.6 (95% CI 37.3–48.0), 42.0 (95% CI 37.7–46.3), and 1.9 (95% CI 1.6–2.2), respectively. The respondents scoring above critical values indicating clinical burnout ranged between 3% and 18%, respectively, for the four burnout sub‐dimensions. Women reported significantly higher levels of stress and burnout. Younger participants had lower job satisfaction and higher levels of work‐life conflicts, stress, and burnout. Higher perceived workload was significantly associated with lower job satisfaction levels and higher levels of work‐life conflicts, stress, and burnout.Conclusions: Our results indicate associations between MNHCWs perceived workload and job satisfaction, work‐life conflicts, stress, and burnout during the COVID‐19 pandemic. Eighteen percent scored above critical values for exhaustion.
- 30 March 2023
- Published by Wiley in International Journal of Gynecology & Obstetrics
- Vol. 162 (3) , 989-997
Open AccessThe COPE Staff study: Study description and initial report regarding job satisfaction, work‐life conflicts, stress, and burnout among Swedish maternal and neonatal healthcare workers during the COVID‐19 pandemic
Objective: To describe the study design of the COPE Staff cohort study on working conditions for maternal and neonatal healthcare workers (MNHCWs), and present baseline data regarding job satisfaction, work‐life conflicts, stress, and burnout.Methods: Between January and April 2021, 957 MNHCWs (administrative and medical staff) completed a baseline survey. Average levels of job satisfaction, work‐life conflicts, stress, and burnout, and associations to perceived workload were assessed.Results: The average levels of job satisfaction, work‐life conflicts, stress, and burnout were 68.6 (95% confidence interval [CI] 64.3–72.8), 42.6 (95% CI 37.3–48.0), 42.0 (95% CI 37.7–46.3), and 1.9 (95% CI 1.6–2.2), respectively. The respondents scoring above critical values indicating clinical burnout ranged between 3% and 18%, respectively, for the four burnout sub‐dimensions. Women reported significantly higher levels of stress and burnout. Younger participants had lower job satisfaction and higher levels of work‐life conflicts, stress, and burnout. Higher perceived workload was significantly associated with lower job satisfaction levels and higher levels of work‐life conflicts, stress, and burnout.Conclusions: Our results indicate associations between MNHCWs perceived workload and job satisfaction, work‐life conflicts, stress, and burnout during the COVID‐19 pandemic. Eighteen percent scored above critical values for exhaustion.
- Open Access
- 5 April 2022
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 139 (5) , 764-770
Method of Hormonal Contraception and Protective Effects Against Ectopic Pregnancy
OBJECTIVE: To estimate the incidence rates for ectopic pregnancy by contraceptive method in a cohort of women using hormonal contraception in Sweden between 2005 and 2016. METHOD: Women aged 15–49 years with a filled prescription for a hormonal contraceptive in the Swedish Prescribed Drug Register between 2005 and 2016 were included. For each woman, all exposed woman-years were allocated to treatment episodes depending on the method of contraception. Treatment time started on the day the prescription was filled and ended on the first day of the end of supply, new eligible dispensing, pregnancy-related diagnosis and its associated estimated last menstrual period, or removal procedure. Ectopic pregnancy was defined as having at least two records of International Classification of Diseases, Tenth Revision code O00-, including O00.0, O00.1, O00.2, O00.8, O00.9, within 30 days or one episode of O00- and one surgical procedure for ectopic pregnancy (NOMESCO Classification of Surgical Procedures code LBA, LBC, LBD, LBE, LBW). Incidence rates per 1,000 woman-years and 95% CIs were calculated for each method of contraception. RESULTS: The study included 1,663,242 women and 1,915 events of ectopic pregnancy. The incidence rate (95% CI) for ectopic pregnancy per method of hormonal contraception was estimated: 13.5-mg levonorgestrel (LNG) hormonal intrauterine device (IUD), 2.76 (2.26–3.35) per 1,000 woman-years; 52-mg LNG hormonal IUD, 0.30 (0.28–0.33) per 1,000 woman-years; combined oral contraception, 0.20 (0.19–0.22) per 1,000 woman-years; progestogen implants, 0.31 (0.26–0.37) per 1,000 woman-years; oral medium-dose progestogen (desogestrel 75 mg), 0.24 per 1,000 woman-years, (0.21–0.27); and oral low-dose progestogen (norethisterone 0.35 mg and lynestrenol 0.5 mg), 0.81 (0.70–0.93) per 1,000 woman-years. CONCLUSION: Hormonal contraception lowers the risk of ectopic pregnancy markedly. The incidence rate of ectopic pregnancy among women using a low-dose hormonal IUD (13.5 mg LNG) was substantially higher than that in women using other types of hormonal contraception. This study provides real-world evidence to inform best clinical practice for women-centered contraceptive counseling.
- 5 April 2022
- Published by Wolters Kluwer Health in Obstetrics & Gynecology
- Vol. 139 (5) , 764-770
Open AccessMethod of Hormonal Contraception and Protective Effects Against Ectopic Pregnancy
OBJECTIVE: To estimate the incidence rates for ectopic pregnancy by contraceptive method in a cohort of women using hormonal contraception in Sweden between 2005 and 2016. METHOD: Women aged 15–49 years with a filled prescription for a hormonal contraceptive in the Swedish Prescribed Drug Register between 2005 and 2016 were included. For each woman, all exposed woman-years were allocated to treatment episodes depending on the method of contraception. Treatment time started on the day the prescription was filled and ended on the first day of the end of supply, new eligible dispensing, pregnancy-related diagnosis and its associated estimated last menstrual period, or removal procedure. Ectopic pregnancy was defined as having at least two records of International Classification of Diseases, Tenth Revision code O00-, including O00.0, O00.1, O00.2, O00.8, O00.9, within 30 days or one episode of O00- and one surgical procedure for ectopic pregnancy (NOMESCO Classification of Surgical Procedures code LBA, LBC, LBD, LBE, LBW). Incidence rates per 1,000 woman-years and 95% CIs were calculated for each method of contraception. RESULTS: The study included 1,663,242 women and 1,915 events of ectopic pregnancy. The incidence rate (95% CI) for ectopic pregnancy per method of hormonal contraception was estimated: 13.5-mg levonorgestrel (LNG) hormonal intrauterine device (IUD), 2.76 (2.26–3.35) per 1,000 woman-years; 52-mg LNG hormonal IUD, 0.30 (0.28–0.33) per 1,000 woman-years; combined oral contraception, 0.20 (0.19–0.22) per 1,000 woman-years; progestogen implants, 0.31 (0.26–0.37) per 1,000 woman-years; oral medium-dose progestogen (desogestrel 75 mg), 0.24 per 1,000 woman-years, (0.21–0.27); and oral low-dose progestogen (norethisterone 0.35 mg and lynestrenol 0.5 mg), 0.81 (0.70–0.93) per 1,000 woman-years. CONCLUSION: Hormonal contraception lowers the risk of ectopic pregnancy markedly. The incidence rate of ectopic pregnancy among women using a low-dose hormonal IUD (13.5 mg LNG) was substantially higher than that in women using other types of hormonal contraception. This study provides real-world evidence to inform best clinical practice for women-centered contraceptive counseling.
- Open Access
- 10 January 2022
- Published by Elsevier in Sexual & Reproductive Healthcare
- Vol. 31, 100695
Vietnamese midwives' experiences of working in maternity care – A qualitative study in the Hanoi region
- 10 January 2022
- Published by Elsevier in Sexual & Reproductive Healthcare
- Vol. 31, 100695
Open AccessVietnamese midwives' experiences of working in maternity care – A qualitative study in the Hanoi region
- 8 February 2019
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 98 (7) , 937-943
Levonorgestrel intrauterine contraceptive systems (13.5 mg and 52 mg) and risk of ectopic pregnancy
Introduction The objective was to investigate the Pearl index for ectopic pregnancy in women using levonorgestrel intrauterine system (LNG‐IUS) at time of conception. Material and Methods This was a sub‐study of a hospital based historical cohort including women with an ectopic pregnancy diagnosed in four referral hospitals in Stockholm Sweden between December 2013 and April 2017. Study participants and type of contraception at time of conception were identified through the electronic medical chart system. Cases were defined as women with LNG‐IUS 13.5 mg or 52 mg in situ at the time of diagnosis of ectopic pregnancy who had their LNG‐IUS inserted 1st January 2014 or later. Outcome was defined as the incidence rate for ectopic pregnancy during use per 100 women‐year (Pearl index) with 95% confidence interval. Results The study includes 35 cases with LNG‐IUS 13.5 mg and 13 cases with LNG‐IUS 52 mg, which occurred in 18488 (13.5 mg) and 50246 (52 mg) exposed women years. Pearl index for ectopic pregnancy was estimated to 0.19 (95% CI 0.15 to 0.28) for LNG‐IUS 13.5 mg and to 0.006 (95% CI 0.00 to 0.01) for LNG‐IUS 52 mg. The majority of cases for the LNG‐IUS 13.5 mg (n=26; 74%) occurred during the first year of use with a corresponding Pearl index at 0.23 (95% CI 0.14 to 0.35). Conclusions The absolute risk of ectopic pregnancy during the use of LNG‐IUS remains low. Our method may under‐ as well as overestimate the Pearl index for ectopic pregnancy. The findings underline the importance of identifying risk factors for ectopic pregnancy at insertion, and to rule out ectopic pregnancy for all women presenting with abdominal discomfort during the use of LNG‐IUS. Longer observation periods and prospective studies in a general population are a priority for further research.
- 8 February 2019
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 98 (7) , 937-943
Levonorgestrel intrauterine contraceptive systems (13.5 mg and 52 mg) and risk of ectopic pregnancy
Introduction The objective was to investigate the Pearl index for ectopic pregnancy in women using levonorgestrel intrauterine system (LNG‐IUS) at time of conception. Material and Methods This was a sub‐study of a hospital based historical cohort including women with an ectopic pregnancy diagnosed in four referral hospitals in Stockholm Sweden between December 2013 and April 2017. Study participants and type of contraception at time of conception were identified through the electronic medical chart system. Cases were defined as women with LNG‐IUS 13.5 mg or 52 mg in situ at the time of diagnosis of ectopic pregnancy who had their LNG‐IUS inserted 1st January 2014 or later. Outcome was defined as the incidence rate for ectopic pregnancy during use per 100 women‐year (Pearl index) with 95% confidence interval. Results The study includes 35 cases with LNG‐IUS 13.5 mg and 13 cases with LNG‐IUS 52 mg, which occurred in 18488 (13.5 mg) and 50246 (52 mg) exposed women years. Pearl index for ectopic pregnancy was estimated to 0.19 (95% CI 0.15 to 0.28) for LNG‐IUS 13.5 mg and to 0.006 (95% CI 0.00 to 0.01) for LNG‐IUS 52 mg. The majority of cases for the LNG‐IUS 13.5 mg (n=26; 74%) occurred during the first year of use with a corresponding Pearl index at 0.23 (95% CI 0.14 to 0.35). Conclusions The absolute risk of ectopic pregnancy during the use of LNG‐IUS remains low. Our method may under‐ as well as overestimate the Pearl index for ectopic pregnancy. The findings underline the importance of identifying risk factors for ectopic pregnancy at insertion, and to rule out ectopic pregnancy for all women presenting with abdominal discomfort during the use of LNG‐IUS. Longer observation periods and prospective studies in a general population are a priority for further research.
- Open Access
Neuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study
Objective To evaluate the possible effects of exposure to neuraminidase inhibitors during embryo-fetal life with respect to adverse neonatal outcomes and congenital malformations. Design Population based multinational observational cohort study and meta-analysis. Setting National registers covering information on maternal healthcare, births, and prescriptions in Denmark, Norway, and Sweden and the EFEMERIS database from the Haute-Garonne district in France. Participants All women together with their singleton infants born between 1 January 2008 and 31 December 2010. Only infants born at 154 days of gestation or later were included. Infants were defined as exposed if the women filled a prescription during pregnancy for either of the two neuraminidase inhibitors oseltamivir or zanamivir. Main outcomes Low birth weight, low Apgar score, preterm birth, small for gestational age birth, stillbirth, neonatal mortality, neonatal morbidity, and congenital malformations. Crude and adjusted hazard ratios of preterm birth were estimated using Cox regression models. Crude and adjusted odds ratios for other outcomes were estimated by logistic regression models. Results The study included 5824 (0.8%) exposed women and their infants and 692 232 who were not exposed. Exposure to neuraminidase inhibitors in utero was not associated with increased risks of any of the investigated neonatal outcomes, including low birth weight (adjusted odds ratio 0.77, 95% confidence interval 0.65 to 0.91), low Apgar score (adjusted odds ratio 0.87, 0.67 to 1.14), preterm birth (adjusted hazard ratio 0.97, 0.86 to 1.10), small for gestational age birth (adjusted odds ratio 0.72, 0.59 to 0.87), stillbirth (adjusted odds ratio 0.81, 0.51 to 1.30), neonatal mortality (adjusted odds ratio 1.13, 0.56 to 2.28), and neonatal morbidity (adjusted odds ratio 0.92, 0.86 to 1.00). No increased risk of congenital malformations overall associated with maternal exposure was observed during the first trimester (adjusted odds ratio 1.06, 0.77 to 1.48). Similarly, no significantly increased risks of any of the outcomes were observed in an analysis restricted to oseltamivir alone. Conclusions This large multinational register study found no increased risks of adverse neonatal outcomes or congenital malformations associated with exposure to neuraminidase inhibitors during embryo-fetal life. The results support previously reported findings that the use of neuraminidase inhibitors is not associated with increased risks of adverse fetal or neonatal outcomes.
Open AccessNeuraminidase inhibitors during pregnancy and risk of adverse neonatal outcomes and congenital malformations: population based European register study
Objective To evaluate the possible effects of exposure to neuraminidase inhibitors during embryo-fetal life with respect to adverse neonatal outcomes and congenital malformations. Design Population based multinational observational cohort study and meta-analysis. Setting National registers covering information on maternal healthcare, births, and prescriptions in Denmark, Norway, and Sweden and the EFEMERIS database from the Haute-Garonne district in France. Participants All women together with their singleton infants born between 1 January 2008 and 31 December 2010. Only infants born at 154 days of gestation or later were included. Infants were defined as exposed if the women filled a prescription during pregnancy for either of the two neuraminidase inhibitors oseltamivir or zanamivir. Main outcomes Low birth weight, low Apgar score, preterm birth, small for gestational age birth, stillbirth, neonatal mortality, neonatal morbidity, and congenital malformations. Crude and adjusted hazard ratios of preterm birth were estimated using Cox regression models. Crude and adjusted odds ratios for other outcomes were estimated by logistic regression models. Results The study included 5824 (0.8%) exposed women and their infants and 692 232 who were not exposed. Exposure to neuraminidase inhibitors in utero was not associated with increased risks of any of the investigated neonatal outcomes, including low birth weight (adjusted odds ratio 0.77, 95% confidence interval 0.65 to 0.91), low Apgar score (adjusted odds ratio 0.87, 0.67 to 1.14), preterm birth (adjusted hazard ratio 0.97, 0.86 to 1.10), small for gestational age birth (adjusted odds ratio 0.72, 0.59 to 0.87), stillbirth (adjusted odds ratio 0.81, 0.51 to 1.30), neonatal mortality (adjusted odds ratio 1.13, 0.56 to 2.28), and neonatal morbidity (adjusted odds ratio 0.92, 0.86 to 1.00). No increased risk of congenital malformations overall associated with maternal exposure was observed during the first trimester (adjusted odds ratio 1.06, 0.77 to 1.48). Similarly, no significantly increased risks of any of the outcomes were observed in an analysis restricted to oseltamivir alone. Conclusions This large multinational register study found no increased risks of adverse neonatal outcomes or congenital malformations associated with exposure to neuraminidase inhibitors during embryo-fetal life. The results support previously reported findings that the use of neuraminidase inhibitors is not associated with increased risks of adverse fetal or neonatal outcomes.